The use of regular aspirin by individuals aged 40 and older who have been newly diagnosed with type 2 diabetes is a cost-effective treatment strategy, according to a study in the June issue of Diabetes Care, as reported by HealthDay News.
The use of regular aspirin by individuals aged 40 and older who have been newly diagnosed with type 2 diabetes is a cost-effective treatment strategy, according to a study in the June issue of Diabetes Care, as reported by HealthDay News.
Rui Li, PhD, of the Centers for Disease Control and Prevention in Atlanta, and colleagues used a Markov disease progression model of type 2 diabetes to evaluate the cost-effectiveness of the daily use of aspirin (80 mg) in adults aged 40 to 94 who were newly diagnosed in 2006. The model analyzed lifetime costs for 5 typical diabetes complications: neuropathy, nephropathy, retinopathy, coronary heart disease, and stroke.
The researchers found that aspirin users gained 0.31 life-years or 0.19 quality-adjusted life-years (QALYs) over a lifetime compared with those not taking aspirin. The incremental cost was $1,700. The incremental cost-effectiveness ratio (ICER) of aspirin use was $5,428 per life-year gained or $8,801 per QALY gained.
Medicare and Medicaid programs cover many drugs and medical technologies with much higher ICERs than the estimated ICER for aspirin, according to the authors. “The daily use of aspirin among people with newly diagnosed diabetes who do not have a history of cardiovascular disease is cost effective when compared with people who are not using aspirin,” Dr. Li told Formulary.
Therapy-wise, the health benefits of aspirin outweigh any side effects based on currently available information, Dr. Li said.
More trial data is needed to study the efficacy of aspirin for the primary prevention of cardiovascular disease in individuals with diabetes, Dr. Li said.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More